XML 49 R39.htm IDEA: XBRL DOCUMENT v3.20.2
INVESTMENTS - RELATED PARTIES (Tables)
 6 Months Ended
Jun. 30, 2020
Investments, Debt and Equity Securities [Abstract]  
Schedule of investments

Investments in AVLP and Alzamend Neuro, Inc. (“Alzamend”) at June 30, 2020 and December 31, 2019, are comprised of the following:

 

  June 30,   December 31,
  2020   2019
Investment in convertible promissory note of AVLP $        9,802,686   $        9,595,079
Accrued interest in convertible promissory note of AVLP 2,025,475   2,025,475
Total investment in convertible promissory note of AVLP – Gross 11,828,161   11,620,554
Less: provision for loan losses (5,088,927)   (5,079,834)
Total investment in convertible promissory note of AVLP $        6,739,234   $        6,540,720
       
Investment in derivative instruments of AVLP 858,564   1,330,684
Investment in common stock of AVLP 169,860   238,602
Investment in common stock of Alzamend 575,925   558,938
Investment in derivative instruments and common stock of AVLP and Alzamend $        1,604,349   $        2,128,224
       
Total investment in AVLP and Alzamend – Net $        8,343,583   $        8,668,944
       
Investment in warrants and common stock of AVLP and Alzamend $        1,604,349   $        2,128,224
Investment in convertible promissory note of AVLP 6,739,234   6,540,720
Total investment in AVLP and Alzamend – Net $        8,343,583   $        8,668,944
Schedule of summarizes the changes in our investments

The following table summarizes the changes in our investments in AVLP and Alzamend during the six months ended June 30, 2020: 

 

    Investment in        
    warrants and   Investment in   Total
    common stock   convertible   investment
    of AVLP and   promissory   in AVLP and
    Alzamend   note of AVLP   Alzamend – Net
Balance at January 1, 2020   $       2,128,224   $     6,540,720   $          8,668,944
Investment in convertible promissory notes of AVLP    —   198,514   198,514
Investment in common stock of AVLP and Alzamend   12,884    —          12,884
Fair value of derivative instruments issued by AVLP   9,093    —           9,093
Unrealized loss in derivative instruments of AVLP   (481,213)    —   (481,213)
Unrealized loss in common stock of AVLP and Alzamend   (64,639)    —   (64,639)
Balance at June 30, 2020   $       1,604,349   $     6,739,234   $          8,343,583